JP2024023349A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024023349A5 JP2024023349A5 JP2023196825A JP2023196825A JP2024023349A5 JP 2024023349 A5 JP2024023349 A5 JP 2024023349A5 JP 2023196825 A JP2023196825 A JP 2023196825A JP 2023196825 A JP2023196825 A JP 2023196825A JP 2024023349 A5 JP2024023349 A5 JP 2024023349A5
- Authority
- JP
- Japan
- Prior art keywords
- liposome
- composition
- compound
- peg
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002502 liposome Substances 0.000 claims 30
- 239000000203 mixture Substances 0.000 claims 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 9
- 235000012000 cholesterol Nutrition 0.000 claims 7
- 150000003904 phospholipids Chemical class 0.000 claims 7
- 239000002202 Polyethylene glycol Substances 0.000 claims 5
- 150000002632 lipids Chemical class 0.000 claims 5
- 229920001223 polyethylene glycol Polymers 0.000 claims 5
- 229920000642 polymer Polymers 0.000 claims 5
- 150000001412 amines Chemical group 0.000 claims 4
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000012530 fluid Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 229940125898 compound 5 Drugs 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 229940126062 Compound A Drugs 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025282870A JP2026053650A (ja) | 2016-01-11 | 2025-12-25 | 血管拡張性失調症及びＲａｄ３関連タンパク質（ＡＴＲ）の阻害 |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662277262P | 2016-01-11 | 2016-01-11 | |
| US62/277,262 | 2016-01-11 | ||
| US201662420258P | 2016-11-10 | 2016-11-10 | |
| US62/420,258 | 2016-11-10 | ||
| US201762444172P | 2017-01-09 | 2017-01-09 | |
| US62/444,172 | 2017-01-09 | ||
| JP2018554659A JP6918829B2 (ja) | 2016-01-11 | 2017-01-11 | 血管拡張性失調症及びＲａｄ３関連タンパク質（ＡＴＲ）の阻害 |
| JP2021120731A JP7439023B2 (ja) | 2016-01-11 | 2021-07-21 | 血管拡張性失調症及びＲａｄ３関連タンパク質（ＡＴＲ）の阻害 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021120731A Division JP7439023B2 (ja) | 2016-01-11 | 2021-07-21 | 血管拡張性失調症及びＲａｄ３関連タンパク質（ＡＴＲ）の阻害 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025282870A Division JP2026053650A (ja) | 2016-01-11 | 2025-12-25 | 血管拡張性失調症及びＲａｄ３関連タンパク質（ＡＴＲ）の阻害 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024023349A JP2024023349A (ja) | 2024-02-21 |
| JP2024023349A5 true JP2024023349A5 (https=) | 2024-05-24 |
Family
ID=59311885
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554659A Active JP6918829B2 (ja) | 2016-01-11 | 2017-01-11 | 血管拡張性失調症及びＲａｄ３関連タンパク質（ＡＴＲ）の阻害 |
| JP2021120731A Active JP7439023B2 (ja) | 2016-01-11 | 2021-07-21 | 血管拡張性失調症及びＲａｄ３関連タンパク質（ＡＴＲ）の阻害 |
| JP2023196825A Pending JP2024023349A (ja) | 2016-01-11 | 2023-11-20 | 血管拡張性失調症及びＲａｄ３関連タンパク質（ＡＴＲ）の阻害 |
| JP2025282870A Pending JP2026053650A (ja) | 2016-01-11 | 2025-12-25 | 血管拡張性失調症及びＲａｄ３関連タンパク質（ＡＴＲ）の阻害 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554659A Active JP6918829B2 (ja) | 2016-01-11 | 2017-01-11 | 血管拡張性失調症及びＲａｄ３関連タンパク質（ＡＴＲ）の阻害 |
| JP2021120731A Active JP7439023B2 (ja) | 2016-01-11 | 2021-07-21 | 血管拡張性失調症及びＲａｄ３関連タンパク質（ＡＴＲ）の阻害 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025282870A Pending JP2026053650A (ja) | 2016-01-11 | 2025-12-25 | 血管拡張性失調症及びＲａｄ３関連タンパク質（ＡＴＲ）の阻害 |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US10570119B2 (https=) |
| EP (3) | EP3936153B1 (https=) |
| JP (4) | JP6918829B2 (https=) |
| KR (2) | KR102461219B1 (https=) |
| CN (2) | CN116211803B (https=) |
| AU (3) | AU2017207299B2 (https=) |
| DK (2) | DK3936153T3 (https=) |
| ES (2) | ES2997263T3 (https=) |
| FI (1) | FI3936153T3 (https=) |
| HR (1) | HRP20241512T1 (https=) |
| IL (2) | IL313681A (https=) |
| MA (1) | MA43870A (https=) |
| MX (1) | MX2018008507A (https=) |
| PL (1) | PL3402532T3 (https=) |
| PT (1) | PT3936153T (https=) |
| SI (1) | SI3936153T1 (https=) |
| WO (1) | WO2017123588A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3936153B1 (en) * | 2016-01-11 | 2024-08-21 | Celator Pharmaceuticals, Inc. | Inhibiting ataxia telangiectasia and rad3-related protein (atr) |
| JP7482487B2 (ja) * | 2018-09-13 | 2024-05-14 | タイワン リポソーム カンパニー リミテッド | 鎮静薬を含む徐放性医薬組成物およびその使用 |
| TWI767149B (zh) * | 2018-10-17 | 2022-06-11 | 台灣微脂體股份有限公司 | 含有免疫調節劑的緩釋藥物組合物及其用途 |
| US20230190752A1 (en) * | 2020-05-07 | 2023-06-22 | Washington University | Compositions and methods for predicting therapeutic outcome |
| WO2021258013A1 (en) | 2020-06-18 | 2021-12-23 | Akagera Medicines, Inc. | Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and methods of use thereof |
| EP4210692A4 (en) * | 2020-09-14 | 2024-10-02 | Zhuhai Beihai Biotech Co., Ltd. | Formulations of cabazitaxel |
| EP4230628B1 (en) | 2020-10-16 | 2025-10-15 | Shanghai de Novo Pharmatech Co., Ltd. | Triheterocyclic derivative, and pharmaceutical composition and application thereof |
| TW202517268A (zh) * | 2023-07-14 | 2025-05-01 | 美商塞萊托藥品股份有限公司 | 包含ａｔｒ抑制劑之脂質體組合物之使用方法 |
| EP4694883A2 (en) * | 2023-07-14 | 2026-02-18 | Jazz Pharmaceuticals Therapeutics, Inc. | Combinations comprising an atr inhibitor and a parp inhibitor and methods of use thereof |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4990610A (en) | 1988-08-25 | 1991-02-05 | Applied Analytical Industries, Inc. | Method for preparing high potency sucralfate |
| US5043164A (en) | 1989-01-17 | 1991-08-27 | The University Of Tennessee Research Corporation | Blood-stable, cholesterol-free liposomes |
| SE0102439D0 (sv) | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| SE0203752D0 (sv) | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
| CA2517720A1 (en) | 2003-03-11 | 2004-09-23 | Pfizer Products Inc. | Pyrazine compounds as transforming growth factor (tgf) inhibitors |
| ES2559828T3 (es) | 2003-07-16 | 2016-02-16 | Protiva Biotherapeutics Inc. | ARN de interferencia encapsulado en lípidos |
| CA2928387A1 (en) | 2004-05-03 | 2005-11-17 | Merrimack Pharmaceuticals, Inc. | Drug delivery liposomes containing anionic polyols or anionic sugars |
| GB0411401D0 (en) | 2004-05-21 | 2004-06-23 | Tissuomics Ltd | Penetrating radiation measurements |
| AU2005272586A1 (en) | 2004-08-19 | 2006-02-23 | Icos Corporation | Compounds useful for inhibiting CHK1 |
| GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| EP1888550B1 (en) | 2005-05-12 | 2014-06-25 | AbbVie Bahamas Ltd. | Apoptosis promoters |
| WO2007015632A1 (en) | 2005-08-04 | 2007-02-08 | Cgk Co., Ltd. | Atm and atr inhibitor |
| CA2662320C (en) | 2006-09-05 | 2014-07-22 | Abbott Laboratories | Bcl inhibitors treating platelet excess |
| US20100215582A1 (en) | 2007-05-14 | 2010-08-26 | Konica Minolta Holdings, Inc. | Liposome and method for producing liposome |
| KR20170015566A (ko) | 2008-11-10 | 2017-02-08 | 버텍스 파마슈티칼스 인코포레이티드 | Ａｔｒ 키나제의 억제제로서 유용한 화합물 |
| US8884870B2 (en) | 2008-12-19 | 2014-11-11 | Immersion Corporation | Interactive painting game and associated controller |
| ES2663222T3 (es) | 2008-12-19 | 2018-04-11 | Vertex Pharmaceuticals Incorporated | Derivados de pirazina útiles como inhibidores de la quinasa ATR |
| US20110053923A1 (en) * | 2008-12-22 | 2011-03-03 | Astrazeneca | Chemical compounds 610 |
| WO2011029842A1 (en) | 2009-09-10 | 2011-03-17 | Novartis Ag | Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer |
| US9630956B2 (en) | 2010-05-12 | 2017-04-25 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| JP5856151B2 (ja) | 2010-05-12 | 2016-02-09 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼ阻害剤として有用な２−アミノピリジン誘導体 |
| JP2013526539A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用なピラジン |
| JP2013529200A (ja) | 2010-05-12 | 2013-07-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| US8969356B2 (en) | 2010-05-12 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| JP2013526540A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| CA2803802A1 (en) | 2010-06-23 | 2011-12-29 | Vertex Pharmaceuticals Incorporated | Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase |
| CN102485213A (zh) * | 2010-12-01 | 2012-06-06 | 沈阳药科大学 | 伊立替康脂质体及其制备方法 |
| CN102485212B (zh) * | 2010-12-01 | 2014-04-09 | 沈阳药科大学 | 苹果酸舒尼替尼脂质体及其制备方法 |
| JP2014510151A (ja) | 2011-04-05 | 2014-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ（ｔｒａｋｉｎａｓｅ）阻害剤として有用なアミノピラジン化合物 |
| EP2723745A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| WO2012178124A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2012178125A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| KR20140084112A (ko) * | 2011-09-30 | 2014-07-04 | 버텍스 파마슈티칼스 인코포레이티드 | Ａｔｒ 키나제의 억제제로서 유용한 화합물 |
| US8853217B2 (en) | 2011-09-30 | 2014-10-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| WO2013049719A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2013049859A1 (en) * | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors |
| SG10201606774UA (en) | 2011-09-30 | 2016-10-28 | Vertex Pharma | Processes for making compounds useful as inhibitors of atr kinase |
| WO2013071094A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| US8841337B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| WO2013071088A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| US8841450B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| WO2013071085A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
| CA2869309C (en) | 2012-04-05 | 2021-02-09 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase and combination therapies thereof |
| US8999632B2 (en) | 2012-10-04 | 2015-04-07 | Vertex Pharmaceuticals Incorporated | Method for measuring ATR inhibition mediated increases in DNA damage |
| US8912198B2 (en) * | 2012-10-16 | 2014-12-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| SI2941432T1 (en) | 2012-12-07 | 2018-07-31 | Vertex Pharmaceuticals Incorporated | 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR |
| EP2970289A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| WO2014143242A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| JP2016512815A (ja) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体 |
| LT3157566T (lt) | 2014-06-17 | 2019-08-12 | Vertex Pharmaceuticals Incorporated | Vėžio gydymo būdas, panaudojant chk1 ir atr inhibitorių derinį |
| WO2016004043A1 (en) * | 2014-06-30 | 2016-01-07 | Blend Therapeutics, Inc. | Targeted conjugates and particles and formulations thereof |
| HK1258570A1 (zh) | 2015-09-30 | 2019-11-15 | Vertex Pharmaceuticals Inc. | 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法 |
| EP3936153B1 (en) * | 2016-01-11 | 2024-08-21 | Celator Pharmaceuticals, Inc. | Inhibiting ataxia telangiectasia and rad3-related protein (atr) |
-
2017
- 2017-01-11 EP EP21182826.4A patent/EP3936153B1/en active Active
- 2017-01-11 ES ES21182826T patent/ES2997263T3/es active Active
- 2017-01-11 DK DK21182826.4T patent/DK3936153T3/da active
- 2017-01-11 MX MX2018008507A patent/MX2018008507A/es unknown
- 2017-01-11 JP JP2018554659A patent/JP6918829B2/ja active Active
- 2017-01-11 PL PL17738831.1T patent/PL3402532T3/pl unknown
- 2017-01-11 FI FIEP21182826.4T patent/FI3936153T3/fi active
- 2017-01-11 AU AU2017207299A patent/AU2017207299B2/en active Active
- 2017-01-11 CN CN202310263334.7A patent/CN116211803B/zh active Active
- 2017-01-11 CN CN201780011422.0A patent/CN108697811B/zh active Active
- 2017-01-11 DK DK17738831.1T patent/DK3402532T3/da active
- 2017-01-11 IL IL313681A patent/IL313681A/en unknown
- 2017-01-11 WO PCT/US2017/012939 patent/WO2017123588A1/en not_active Ceased
- 2017-01-11 US US16/069,092 patent/US10570119B2/en active Active
- 2017-01-11 PT PT211828264T patent/PT3936153T/pt unknown
- 2017-01-11 EP EP17738831.1A patent/EP3402532B1/en active Active
- 2017-01-11 ES ES17738831T patent/ES2921008T3/es active Active
- 2017-01-11 EP EP24194804.1A patent/EP4438127A3/en active Pending
- 2017-01-11 MA MA043870A patent/MA43870A/fr unknown
- 2017-01-11 HR HRP20241512TT patent/HRP20241512T1/hr unknown
- 2017-01-11 KR KR1020187022169A patent/KR102461219B1/ko active Active
- 2017-01-11 IL IL260487A patent/IL260487B2/en unknown
- 2017-01-11 SI SI201731565T patent/SI3936153T1/sl unknown
- 2017-01-11 KR KR1020227037451A patent/KR102558501B1/ko active Active
-
2020
- 2020-01-17 US US16/745,709 patent/US11028076B2/en active Active
-
2021
- 2021-05-07 US US17/314,753 patent/US11787781B2/en active Active
- 2021-07-21 JP JP2021120731A patent/JP7439023B2/ja active Active
-
2023
- 2023-09-01 US US18/460,047 patent/US20230416236A1/en not_active Abandoned
- 2023-11-20 JP JP2023196825A patent/JP2024023349A/ja active Pending
- 2023-12-15 AU AU2023282309A patent/AU2023282309B2/en active Active
-
2024
- 2024-11-07 US US18/940,070 patent/US20250333396A1/en active Pending
-
2025
- 2025-12-09 AU AU2025279601A patent/AU2025279601A1/en active Pending
- 2025-12-25 JP JP2025282870A patent/JP2026053650A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024023349A5 (https=) | ||
| US8956646B2 (en) | Zwitterionic lipids | |
| US6586559B2 (en) | Polyamide oligomers | |
| US5830430A (en) | Cationic lipids and the use thereof | |
| JP2005504749A5 (https=) | ||
| JP2021522163A5 (https=) | ||
| JP2001527052A5 (https=) | ||
| JP3631755B2 (ja) | ポリオキシエチレン含有脂質二本鎖誘導体 | |
| AU751434B2 (en) | Polyamide oligomers | |
| JP2004511572A (ja) | 標的化送達のための脂質製剤 | |
| JP2020519625A5 (https=) | ||
| PT742789E (pt) | Lipossomas e compostos farmaceuticamente activos e metodos para a sua utilizacao | |
| BR112014022847B1 (pt) | Lipídios aminoácidos, composição vesicular, e kit | |
| JPH08510748A (ja) | リポソームが誘発する生理的副作用の低減 | |
| IE62548B1 (en) | Liposomes with positive excess charge | |
| JPWO2020097384A5 (https=) | ||
| JP2005505521A5 (https=) | ||
| JPWO2019209787A5 (https=) | ||
| JP4723097B2 (ja) | サイトフェクチン二量体およびその使用方法 | |
| CN1088582C (zh) | 能治疗多种疾病具有层状类脂组分的类脂基载体、其组合物及其应用 | |
| US20040213835A1 (en) | Method to reduce liposome-induced complement activation | |
| JPWO2023091490A5 (https=) | ||
| BRPI0717800A2 (pt) | COMPOSIÇÃO DE LIPOSSOMAS SENSÍVEIS AO pH | |
| JPWO2023054241A5 (https=) | ||
| JPWO2024146016A5 (https=) |